Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.70 |
| ▸ | MAOA | P21397 | 10/20 | 0.70 |
| ▸ | KDM1A | O60341 | 9/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.58 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.56 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1669894 | 1.00 | MAOB (0.70) | MAOBMAOAKDM1AKCNH2PARP10 | |
| SCHEMBL13453253 | 1.00 | MAOB (0.70) | MAOBMAOAKDM1AKCNH2PARP10 | |
| Hydrochloric Acid SCHEMBL1668110 | 0.99 | MAOB (0.69) | MAOBMAOAKDM1AKCNH2PARP10 | |
| Hydrochloric Acid SCHEMBL1668108 | 0.99 | MAOB (0.69) | MAOBMAOAKDM1AKCNH2PARP10 | |
| SCHEMBL1667837 | 0.90 | KDM1A (0.59) | MAOBMAOAKDM1AKCNH2 | |
| SCHEMBL12319696 | 0.90 | KDM1A (0.59) | MAOBMAOAKDM1AKCNH2 | |
| SCHEMBL1667835 | 0.90 | KDM1A (0.59) | MAOBMAOAKDM1AKCNH2 | |
| SCHEMBL1667563 | 0.87 | KDM1A (0.70) | MAOBMAOAKDM1APARP10 | |
| SCHEMBL1667515 | 0.87 | MAOB (0.70) | MAOBMAOAKDM1A | |
| SCHEMBL1667565 | 0.87 | KDM1A (0.70) | MAOBMAOAKDM1APARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2486002-B1 | SUBSTITUTED HETEROARYL- AND ARYL- CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | ORYZON GENOMICS SA (ES) | 2019-03-27 | — | — | EP | claimed |
| US-20180284095-A1 | BIOMARKERS ASSOCIATED WITH LSD1 INHIBITORS AND USES THEREOF | ORYZON GENOMICS SA (ES) | 2018-10-04 | — | — | US | claimed |
| US-9616058-B2 | Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use | ORYZON GENOMICS, S.A. (ES) | 2017-04-11 | — | — | US | claimed |
| US-9186337-B2 | Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae | ORYZON GENOMICS S.A. (ES) | 2015-11-17 | — | — | US | claimed |
| US-8946296-B2 | Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use | ORYZON GENOMICS S.A. (ES) | 2015-02-03 | — | — | US | claimed |
| US-20120264823-A1 | SUBSTITUTED HETEROARYL- AND ARYL-CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | ORYZON GENOMICS S.A. | 2012-10-18 | — | — | US | claimed |
| EP-2486002-A1 | SUBSTITUTED HETEROARYL- AND ARYL- CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | Oryzon Genomics, S.A. (ES) | 2012-08-15 | — | — | EP | claimed |
| WO-2011042217-A1 | SUBSTITUTED HETEROARYL- AND ARYL- CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | ORYZON GENOMICS S.A. (ES) | 2011-04-14 | — | — | WO | claimed |
| EP-3430015-B1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2025-08-06 | — | — | EP | disclosed |
| US-12195783-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | ORYZON GENOMICS S.A. (ES) | 2025-01-14 | — | — | US | disclosed |
| EP-3013424-B1 | LSD INHIBITORS FOR MODULATING CANCER STEM CELLS | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2024-09-25 | — | — | EP | disclosed |
| US-20220389478-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | ORYZON GENOMICS SA (ES) | 2022-12-08 | — | — | US | disclosed |
| WO-2021195723-A1 | \"METHODS FOR TREATMENT OF CORONAVIRUS INFECTIONS\ | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2021-10-07 | — | — | WO | disclosed |
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | EPIAXIS THERAPEUTICS PTY LTD (AU) | 2021-06-24 | — | — | US | disclosed |
| EP-2486002-A1 | SUBSTITUTED HETEROARYL- AND ARYL- CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | Oryzon Genomics, S.A. (ES) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011106574-A2 | INHIBITORS FOR ANTIVIRAL USE | ORYZON GENOMICS, S.A. (ES) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011106573-A2 | LYSINE DEMETHYLASE INHIBITORS FOR DISEASES AND DISORDERS ASSOCIATED WITH HEPADNAVIRIDAE | ORYZON GENOMICS, S.A. (ES) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011106105-A2 | INHIBITORS FOR ANTIVIRAL USE | ORYZON GENOMICS, S.A. (ES) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011106106-A2 | LYSINE DEMETHYLASE INHIBITORS FOR DISEASES AND DISORDERS ASSOCIATED WITH HEPADNAVIRIDAE | ORYZON GENOMICS, S.A. (ES) | 2011-09-01 | — | — | WO | disclosed |
| WO-2011042217-A1 | SUBSTITUTED HETEROARYL- AND ARYL- CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | ORYZON GENOMICS S.A. (ES) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389478-A1 | METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR | KDM1B, KDM1A, KDM7A | MAOB 3928/4885MAOA 4155/4885KDM1A 2/4885 |
| US-20180284095-A1 | BIOMARKERS ASSOCIATED WITH LSD1 INHIBITORS AND USES THEREOF | KDM1B, EZH2, DOT1L | MAOB 410/4885MAOA 526/4885KDM1A 5/4885 |
| US-20210186905-A1 | ENHANCING T-CELL FUNCTION AND TREATING A T-CELL DYSFUNCTIONAL DISORDER WITH A COMBINATION OF AN LSD INHIBITOR AND A PD-1 BINDING ANTAGONIST | PDCD1, CD274, PDCD1LG2 | MAOB 36/4885MAOA 54/4885KDM1A 8/4885 |
| US-20120264823-A1 | SUBSTITUTED HETEROARYL- AND ARYL-CYCLOPROPYLAMINE ACETAMIDES AND THEIR USE | CBR1, CNR1, CBR3 | MAOB 569/4885MAOA 555/4885KDM1A 877/4885 |
| US-12195783-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | KDM1B, KDM1A, KDM7A | MAOB 3928/4885MAOA 4155/4885KDM1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.